Key facts
- This page summarizes Gerald Garrett's Form 4 filing for Marker Therapeutics, Inc. (MRKR).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Feb 2022, 16:02.
Gerald Garrett - 17 Feb 2022 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)
- Reporting relationship
- Vice President, Clinical Ops.
- Issuer ticker
- MRKR
- Reported as of
- 17 Feb 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Michael Loiacono, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Gerald Garrett filed Form 4 for Marker Therapeutics, Inc. (MRKR) on 22 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRKR
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 17 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $0.4600
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.